Michel M. van den Heuvel
Radboud University Nijmegen(NL)Utrecht University(NL)Radboud University Medical Center(NL)University Medical Center Utrecht(NL)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Diagnosis and Treatment, Lung Cancer Research Studies, Cancer Genomics and Diagnostics
Most-Cited Works
- → First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer(2017)2,556 cited
- → Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry(2019)1,334 cited
- → Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer(2020)618 cited
- → Comprehensive Health Assessment 3 Months After Recovery From Acute Coronavirus Disease 2019 (COVID-19)(2020)491 cited
- → Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score(2014)430 cited
- → Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)(2017)417 cited